Physician profile
Randy Jeffrey
NPI 1154641348
$1,683.81
in general payments reported to CMS, 2019-2025
14 companies · $711 in 2025
The $711 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.19 · 2020: $27.62 · 2021: $35.93 · 2022: $191 · 2023: $277 · 2024: $425 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $548.11 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $308.10 | 2024-2025 | Farapulse, Watchman Flx |
| Amgen INC. | $198.50 | 2023-2025 | Repatha, Repatha |
| Medtronic, INC. | $148.13 | 2021-2023 | Harmony |
| Impulse Dynamics (USA) INC. | $141.97 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.36 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $50.76 | 2024-2025 | |
| Ge Healthcare | $48.46 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.23 | 2024-2025 | Jardiance |
| Abbott Laboratories | $28.10 | 2022 | |
| Abiomed | $17.19 | 2019 | |
| Merck Sharp & Dohme LLC | $16.55 | 2023 | Verquvo, Steglatro |
| Janssen Pharmaceuticals, INC | $14.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Jeffrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.